(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 14.6B | -8% |
Gross Profit | 10.7B | - |
Cost Of Revenue | 3.9B | -8% |
Operating Income | -2B | -136% |
Operating Expenses | 12.8B | - |
Net Income | -1.2B | -126% |
R&D | 9.6B | - |
G&A | 2.8B | +11% |
Interest Expense | 310MM | -2% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
U.S. stocks were higher on Wednesday, with the Dow leading gains and the S&P 500 setting a closing record, paced drugmaker Merck, while investors looked towards the next piece of inflation data and Federal Reserve commentary for signals on the rate path. Merck & Co advanced 4.96% as the best performer on the Dow after the U.S. Food and Drug Administration approved its therapy for adults suffering from a rare lung condition.
U.S. stocks were higher, with the Dow leading gains on Wednesday, and the S&P 500 setting a closing record, paced by gains in drugmaker Merck, while investors looked towards the next piece of inflation data and Federal Reserve policymaker commentary for signals on the rate path. Merck & Co advanced as the best performer on the Dow after the U.S. Food and Drug Administration approved its therapy for adults suffering from a rare lung condition. The blue-chip Dow sits roughly 1% away from breakin...
The Dow was the best performing of the three major indexes on Wednesday, paced by gains in drugmaker Merck, while as investors looked towards the next piece of inflation data and Federal Reserve policymaker commentary for insight on the rate path. Merck & Co advanced 4.77% as the biggest boost and percentage gained on the Dow after the U.S. Food and Drug Administration approved its therapy for adults suffering from a rare lung condition.
The Food and Drug Administration has approved Winrevair, Merck's (MRK) latest drug to treat pulmonary arterial hypertension, a lung condition. Investors have been anxiously awaiting the approval as the company is set to lose its patent for Keytruda. The drug will help to reduce the risk of death and worsening events in patients by 84%. Yahoo Finance's Anjalee Khemlani joins The Morning Brief to discuss how the treatment could offer a potential path to the upside for Merck. For more expert insigh...
Wall Street's main stock indexes ticked higher on Wednesday, with the blue-chip Dow leading gains in thin trading ahead of crucial economic data, commentary from the Federal Reserve's policymakers and a long holiday weekend. The Dow and the S&P 500 recorded their third consecutive declines in the previous session, as most megacaps were under pressure and stocks struggled to maintain an upwards momentum. Investors looked forward to comments from Fed Board Governor Christopher Waller, who is set...
(Bloomberg) -- Merck & Co. won US approval for a new treatment for a rare, dangerous form of high blood pressure that’s expected to be among the company’s hits as sales from successful older drugs begin fading later this decade. Most Read from BloombergBiden Gains Ground Against Trump in Six Key States, Poll ShowsJapan Amps Up Intervention Threat as Yen Hits Lowest Since 1990Trump’s Net Worth Hits $6.5 Billion, Making Him One of World’s 500 Richest PeopleUsing Your Premium Credit Card May Cost M
Zacks.com users have recently been watching Merck & Co. (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Wall Street's main stock indexes were set to gain at open on Wednesday as chipmakers and growth stocks rebounded in light trading ahead of crucial economic data, commentary from the Federal Reserve's policymakers and a long holiday weekend. The Dow and the S&P 500 recorded their third consecutive declines on Tuesday, as most megacaps were pressured and stocks struggled to maintain an upwards momentum.
U.S. stock index futures inched higher on Wednesday as chipmakers and market-leading growth stocks rebounded in light trading ahead of crucial economic data, commentary from the Federal Reserve's policymakers and a long holiday weekend. The Dow and the S&P 500 recorded their third consecutive declines on Tuesday, as most megacaps were pressured and stocks struggled to maintain an upwards momentum.
RAHWAY, N.J., March 26, 2024--FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension